Convalescent plasma of no benefit in sick COVID-19 patients
The therapy - a transfusion of plasma from recovered virus patients - did not reduce the risk of death, shows an Argentinian study
Using blood plasma from COVID-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus has little benefit, according to data from a clinical trial in Argentina.
The therapy know as convalescent plasma, which delivers antibodies from COVID-19 patients to infected people, did not significantly improve patients’ health status or reduce their risk of dying from the disease any better than a placebo, the study shows
